1. Home
  2. KZR vs TACT Comparison

KZR vs TACT Comparison

Compare KZR & TACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KZR
    SELLHOLDBUYas of 18 hours ago
  • TACT
    SELLHOLDBUYas of 4 days ago
  • Stock Information
  • Founded
  • KZR 2015
  • TACT 1996
  • Country
  • KZR United States
  • TACT United States
  • Employees
  • KZR N/A
  • TACT N/A
  • Industry
  • KZR Biotechnology: Pharmaceutical Preparations
  • TACT Computer peripheral equipment
  • Sector
  • KZR Health Care
  • TACT Technology
  • Exchange
  • KZR Nasdaq
  • TACT Nasdaq
  • Market Cap
  • KZR 44.1M
  • TACT N/A
  • IPO Year
  • KZR 2018
  • TACT 1996
  • Fundamental
  • Price
  • KZR $4.88
  • TACT $3.67
  • Analyst Decision
  • KZR Hold
  • TACT Strong Buy
  • Analyst Count
  • KZR 2
  • TACT 1
  • Target Price
  • KZR $9.00
  • TACT $7.50
  • AVG Volume (30 Days)
  • KZR 22.4K
  • TACT 18.1K
  • Earning Date
  • KZR 03-25-2025
  • TACT 03-13-2025
  • Dividend Yield
  • KZR N/A
  • TACT N/A
  • EPS Growth
  • KZR N/A
  • TACT N/A
  • EPS
  • KZR N/A
  • TACT N/A
  • Revenue
  • KZR N/A
  • TACT $43,384,000.00
  • Revenue This Year
  • KZR N/A
  • TACT $19.57
  • Revenue Next Year
  • KZR N/A
  • TACT N/A
  • P/E Ratio
  • KZR N/A
  • TACT N/A
  • Revenue Growth
  • KZR N/A
  • TACT N/A
  • 52 Week Low
  • KZR $4.54
  • TACT $3.32
  • 52 Week High
  • KZR $9.30
  • TACT $5.47
  • Technical
  • Relative Strength Index (RSI)
  • KZR 31.03
  • TACT 44.38
  • Support Level
  • KZR $5.01
  • TACT $3.66
  • Resistance Level
  • KZR $6.37
  • TACT $3.84
  • Average True Range (ATR)
  • KZR 0.32
  • TACT 0.18
  • MACD
  • KZR -0.09
  • TACT 0.02
  • Stochastic Oscillator
  • KZR 18.58
  • TACT 53.19

Stock Price Comparison Chart: KZR vs TACT

KZR
TACT
JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober202502468101214161820KZR VS TACT

About KZR Kezar Life Sciences Inc.

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.

Share on Social Networks:

By browsing this website, you accept our Privacy Policy & Terms of Use